Thursday, May 20, 2010

Santhera’s MICONOS Trial with Catena®/Sovrima® in Friedreich’s Ataxia Misses Primary Endpoint

Liestal, Switzerland, May 20, 2010 – Santhera Pharmaceuticals (SIX: SANN) announced today that its MICONOS Phase III study evaluating Catena®/Sovrima® for the treatment of Frie-dreich’s Ataxia missed its primary endpoint. Trends towards improvement in the key neuro-logical endpoint were however identified by a meta-analysis of all Santhera’s Phase II and III studies in the same indication. MICONOS also confirmed that Catena®/Sovrima® is safe and well tolerated at doses of up to 2250 mg/day.